These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 16368298

  • 1. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial.
    Serebruany VL, Pokov AN, Malinin AI, O'Connor C, Bhatt DL, Tanguay JF, Sane DC, Hennekens CH.
    Am Heart J; 2006 Jan; 151(1):92-9. PubMed ID: 16368298
    [Abstract] [Full Text] [Related]

  • 2. Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial.
    Serebruany VL, Pokov AN, Aradi D, Can M, DiNicolantonio J, Kipshidze N, Atar D.
    Am J Ther; 2014 Jan; 21(6):482-90. PubMed ID: 23698186
    [Abstract] [Full Text] [Related]

  • 3. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL, Malinin AI, Pokov AN, Hanley DF.
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [Abstract] [Full Text] [Related]

  • 4. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I.
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [Abstract] [Full Text] [Related]

  • 5. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R.
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The in vitro effects of niacin on platelet biomarkers in human volunteers.
    Serebruany V, Malinin A, Aradi D, Kuliczkowski W, Norgard NB, Boden WE.
    Thromb Haemost; 2010 Aug; 104(2):311-7. PubMed ID: 20539903
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
    Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, Graff A.
    Clin Ther; 2007 Jan; 29(1):61-73. PubMed ID: 17379047
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of valsartan in patients with mild to moderate essential hypertension.
    Nouh MS, Halim SA.
    Saudi Med J; 2002 May; 23(5):521-5. PubMed ID: 12070572
    [Abstract] [Full Text] [Related]

  • 14. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
    Yarows SA, Oparil S, Patel S, Fang H, Zhang J.
    Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
    Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PD, Zhao Y, Grosso A.
    Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
    [Abstract] [Full Text] [Related]

  • 16. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A.
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [Abstract] [Full Text] [Related]

  • 17. Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets.
    McKenzie ME, Malinin AI, Bell CR, Dzhanashvili A, Horowitz ED, Oshrine BR, Atar D, Serebruany VL.
    Blood Coagul Fibrinolysis; 2003 Apr; 14(3):249-53. PubMed ID: 12695747
    [Abstract] [Full Text] [Related]

  • 18. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy.
    Weir MR, Levy D, Crikelair N, Rocha R, Meng X, Glazer R.
    Am J Hypertens; 2007 Jul; 20(7):807-15. PubMed ID: 17586417
    [Abstract] [Full Text] [Related]

  • 19. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.
    Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, Kandra A, Daley WL, Rocha R.
    J Hypertens; 2007 Sep; 25(9):1921-6. PubMed ID: 17762658
    [Abstract] [Full Text] [Related]

  • 20. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
    Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt DL.
    Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.